Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration, FDA, has approved expanded use of Alyftrek for the treatment of people with cystic fibrosis ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator, CFTR, gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for Trikafta in patients ages 2 and older.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Advances FDA Filing for IgA Nephropathy Therapy
- Vertex’s VX-407 Contraceptive Interaction Study Reaches Completion: What Investors Should Watch
- Vertex Pharmaceuticals: Resilient CF Franchise and Advancing Pipeline Support Buy Rating Despite Label Headwinds
- Vertex’s VX-407 Kidney Study Completion: What Phase 1 Progress Means For VRTX Investors
- Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James